TBE Zone 0/1 PMS in Japan
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorW.L.Gore & Associates
About this trial
The goal of this surveillance is to confirm the safety and efficacy of TBE under actual use in the Zone 0/1 lesion on post-marketing usage conditions.
Eligibility criteria
Qualifiers
Thoracic aortic aneurysm
Traumatic transection
Complicated Stanford type A (after surgical repair) and B aortic dissection (including dissecting aortic aneurysm) who have not responded to medical therapy
Disqualifiers
None
Trial design
Treatments tested in this trial
- Gore® TAG® Thoracic Aortic Branch Stent Graft System
Treatment groups
75 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
W.L.Gore & Associates
Lead sponsor
CMIC Co, Ltd. Japan
Collaborator
Source ClinicalTrials.gov